In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni receive FDA 510(k) clearance, secure new funds, complete a first-in-human clinical study, and much more on the road to LSI USA ‘25 in Dana Point, CA (March 17-21).
Secured a $4.5M investment from the European Innovation Council (EIC) Fund, Taiwan Medical University, and private investors. The funds will support the company’s clinical and regulatory efforts for its non-invasive heart failure technology.
Received FDA 510(k) clearance for its Intra-Operative Positioning System (IOPS) Guidewire Handle following the launch of its next-generation Viewpoint catheter and sixth software release. The company also launched the latest advancements to its IOPS software platform.
Successfully performed the first U.S. cases with its surgical robot, Dexter, designed to improve the accessibility of robotic surgery. This milestone comes less than 30 days after being granted FDA De Novo marketing authorization for adult inguinal hernia repair.
Appointed LSI Alumni Kurt Azarbarzin, former CEO of Endoquest Robotics and Verb Surgical and Founder of SurgiQuest, to its Board of Directors. The company’s mission is to improve the standard of women’s health in surgical and in-office procedures to enable physicians to provide safe, effective care.
Announced the first closing of Lauxera Growth II at €300M, representing 75% of its funding target and exceeding the size of its initial fund. Lauxera Capital Partners is an independent, global asset management firm focused on growth equity investments in commercial-stage medical devices, digital health, life sciences tools, and healthcare data.
Published a groundbreaking JMIR aging study validating its AI-driven fall risk prediction system, based on Real-World Data from over 600 seniors. The company develops AI-powered mobility analysis tools, utilizing smartphone cameras to perform 3D motion tracking and assess fall risk, primarily aiding elderly individuals in preventing falls and maintaining mobility.
Announced a name change from NeoPrediX to NeoPredics to align with its strategic vision. NeoPredics is a predictive analytics company that creates proprietary algorithms to assess the risk of various health conditions within neonatal, maternal, and perinatal care.
Successfully completed its first-in-human clinical study. The company’s peripheral nerve stimulation (PNS) device utilizes proprietary technology to improve therapeutic outcomes in the treatment of chronic pain.
Closed on $27.6M in equity funding to accelerate its commercial efforts. This will include a pipeline of new products, growth of its salesforce, expanded surgeon training programs, and the establishment of a flagship U.S. manufacturing site and surgeon training center.
Announced the first close of $4.6M in an anticipated $9M Series B funding. The company also formed a manufacturing partnership with Gentex Corporation for its OtoSignt Middle Ear Scope and relocated its headquarters to Grand Rapids, Michigan.
Secured €2.2M in funding from Irrus Investments, MedTech Syndicate, Boole Investments, Enterprise Ireland, and a new private investor. The funds will support the company’s efforts to obtain U.S. regulatory clearance for its releaze Drainage System.
Appointed Mike Karim as Venture Partner. Karim will oversee business development efforts across the United Kingdom, Europe, and the United States, focusing on managing client relationships and executing fundraising strategies.
Submitted a 510(k) application to the FDA for eSTAR Synova. Synova Life Sciences is a private biotechnology firm focused on creating medical devices and techniques that harness the body’s natural healing ability to address symptoms of degenerative conditions.
Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.
Schedule an exploratory call
Request Info© 2025 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
